Automated blood analysis company, Scopio Labs, secures an additional $10 million in funding for advancements in blood morphology automation technology.
Scopio Labs, a pioneering company in the field of hematology, has launched a groundbreaking AI-based Complete Blood Morphology (CBM) analyzer. This innovative technology is set to reshape the hematology market by automating the previously manual, labor-intensive peripheral blood smear (PBS) review process using AI-powered full-field digital morphology [1].
According to Itai Hayut, CEO and Co-founder of Scopio Labs, the CBM brings unprecedented scale, efficiency, and standardization to hematology diagnostics, addressing a critical bottleneck caused by workforce shortages, long training cycles, and rising diagnostic demand [1].
Key benefits of the CBM analyzer include:
- Automation of a manual diagnostic step: By replacing human-dependent review of PBS with autonomous AI-driven morphology analysis, the CBM reduces variability and improves consistency in results [1].
- Dramatic workflow improvements: Laboratories using Scopio’s platforms have seen marked efficiency gains, readying them for CBM integration. This enables faster turnaround times and scalability in hematology diagnostics, critical for timely patient care [1][2].
- Full-field 100× high-resolution imaging: Unlike other solutions capturing only cell snapshots, Scopio provides comprehensive full-field images, allowing detailed and contextual review without the need for a manual microscope. This improvement supports better clinical decision-making [2].
- Remote collaboration: The digital platform enables hematopathologists and lab teams to securely review and consult remotely across hospital networks, enhancing teamwork and expertise accessibility [2].
- FDA and CE clearance supporting clinical trust: Scopio’s prior FDA clearances (for bone marrow aspirate analysis) and recent groundbreaking clearances for digital blood smear applications reinforce the clinical robustness of the AI platform. This regulatory progress supports adoption and integration in clinical workflows [1][3][5].
- Market impact: By closing the last automation gap in hematology testing after decades of CBC automation, the CBM can improve diagnostic precision and reduce workload burden, potentially revolutionizing how hematology labs operate globally [1].
In addition, Scopio Labs believes that their technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels. The CBM can analyze ten times more cells than current methods, offering the potential for early detection and monitoring of diseases directly from blood [1].
The CBM analyzer will be showcased at the ADLM 2025 Annual Conference. Recent investment from Viola Growth, totaling $52 million in Series D funding, further demonstrates the excitement and confidence in Scopio’s technology [1][4]. Viola Growth views Scopio’s CBM analyzer as a major leap forward for hematology labs and is eager to join Scopio on their journey to reshape the future of hematology diagnostics.
[1] Scopio Labs. (2023). Press Release: Scopio Labs Launches AI-Powered Complete Blood Morphology (CBM) Analyzer.
[2] Scopio Labs. (2023). White Paper: The Future of Hematology Diagnostics with Scopio Labs.
[3] Scopio Labs. (2022). Press Release: Scopio Labs Receives FDA Clearance for Digital Blood Smear Analysis.
[4] Viola Growth. (2023). Press Release: Viola Growth Leads $52 Million Series D Investment in Scopio Labs.
[5] Scopio Labs. (2021). Press Release: Scopio Labs Receives CE Mark for Digital Blood Smear Analysis.
